If you or someone you know has been diagnosed with metastatic breast cancer, please read the following:

* Directly contact of have your doctor contact your nearest clinical site listed on ClinicalTrials.gov as summarized below:

* In a clinical study of 54 patients, Bria-IMT regimen used in combination with an immune check point inhibitor was associated with longer than expected progression free survival and other clinical benefits in metastatic breast cancer patients. The treatment was well-tolerated.

If you have any questions or concerns, please have your oncologist contact us ([email protected]).

Bria-ABC Study (Uses Bria-IMT)

Study Name:

BriaCell Therapeutics Corp. / Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)

The combination study is listed on ClinicalTrials.gov as NCT06072612.


BC1 Study (Uses Bria-OTS)

Study Name:

A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06471673